NCT03007615

Brief Summary

To evaluate the safety of an investigational product through the verification of signs of irritability and sensitization of the genital mucosa, as well as the instrumental moisturizing efficacy by TEWL and barrier integrity analysis, in addition to the efficacy perceived by the volunteers.

Trial Health

50
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
33

participants targeted

Target at P25-P50 for not_applicable

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 29, 2016

Completed
3 days until next milestone

Study Start

First participant enrolled

January 1, 2017

Completed
1 day until next milestone

First Posted

Study publicly available on registry

January 2, 2017

Completed
1 month until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2017

Completed
Last Updated

January 2, 2017

Status Verified

December 1, 2016

Enrollment Period

1 month

First QC Date

December 29, 2016

Last Update Submit

December 29, 2016

Conditions

Outcome Measures

Primary Outcomes (1)

  • Evaluation of the product's efficiency as a moisturizer through subjective evaluation

    30 days

Study Arms (1)

Experimental group

EXPERIMENTAL
Other: Intimate Lubricant Gel

Interventions

Experimental group

Eligibility Criteria

Age45 Years - 65 Years
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Healthy female sex with active sex life;
  • Age group: between 45 and 65 years old;
  • Menopause for at least six months;
  • Whole skin in the region of product analysis;
  • No history of reaction to products of the same category
  • Understanding, agreement and signature of the Term of Free and Informed Consent.

You may not qualify if:

  • Gestation or risk of gestation;
  • Use of anti-inflammatory / immunosuppressive drugs (in the last 30 days and during the study);
  • Active cutaneous pathologies (local and / or disseminated) in the evaluation area;
  • Pathologies that cause suppression of immunity, such as diabetes, HIV, etc.;
  • Endocrine pathologies such as thyroid disorders, ovarian or adrenal gland disorders;
  • Other conditions considered by the investigating physician as reasonable for disqualification of the individual from the study participation.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
SINGLE
Who Masked
PARTICIPANT
Intervention Model
SINGLE GROUP
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 29, 2016

First Posted

January 2, 2017

Study Start

January 1, 2017

Primary Completion

February 1, 2017

Last Updated

January 2, 2017

Record last verified: 2016-12